Dopaminergic Mechanisms in Alzheimer's Disease

Alzheimer’s disease (AD) has traditionally been associated with cholinergic deficits and accumulation of amyloid-β and tau pathology. However, accumulating evidence highlights a crucial role for the dopaminergic system in both cognitive and non-cognitive symptoms of AD. Dopaminergic neurones in the ventral tegmental area (VTA) and their projections to limbic and cortical regions regulate synaptic plasticity, network oscillations and reward processing. Early loss or dysfunction of these neurones leads to reduced dopamine release, alterations in D2-type receptor signalling and impaired parvalbumin interneuron function, which together contribute to network hyperexcitability and memory impairment. Parallel astrocyte-mediated modulation of striatal dopamine release and microglial responses further shapes disease progression. Moreover, in vivo imaging in patients reveals selective vulnerability of the mesocorticolimbic pathway at prodromal stages. These convergent findings underscore dopaminergic mechanisms as both a biomarker and a potential therapeutic target, with implications for symptom management and disease-modifying strategies.

Research from Nature Portfolio

Age-dependent loss of VTA dopaminergic neurones has been shown to precede plaque formation in a transgenic mouse model, resulting in reduced dopamine outflow to hippocampus and nucleus accumbens. This degeneration impairs synaptic plasticity in the CA1 region and disrupts food-reward processing, linking dopaminergic cell death with early memory deficits and motivational changes. In a separate model harbouring both amyloid and tau pathology, early dopaminergic dysfunction manifests as increased postsynaptic D2/3 receptor density in the striatum and heightened D2-autoreceptor sensitivity in the VTA. These alterations coincide with microglial activation and behavioural changes such as altered locomotor activity and anxiety-like responses, suggesting that dopaminergic disturbances emerge before extensive amyloid or tau accumulation and may drive subsequent cognitive decline.

Dopaminergic Mechanisms in Alzheimer's Disease publication trend

The graph below shows the total number of articles in dopaminergic mechanisms in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Dopaminergic innervation: The network of neurones releasing dopamine to modulate target regions.

Ventral Tegmental Area (VTA): A midbrain region housing dopamine-producing neurones that project to limbic and cortical areas.

Dopamine D2 receptor: A G-protein-coupled receptor that mediates inhibitory dopamine signalling in pre- and postsynaptic sites.

Gamma-oscillations: High-frequency network waves (30–100 Hz) associated with cognitive processes and interneuronal synchrony.

Astrocyte: A star-shaped glial cell involved in neurotransmitter regulation, metabolic support and blood-brain barrier maintenance.

Microglia: Resident immune cells of the brain that clear debris and modulate neuroinflammation.

References

1. Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer’s Disease. Molecular Psychiatry (2024).
2. Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer’s disease. Scientific Reports (2021).
3. Impairment of hippocampal astrocyte-mediated striatal dopamine release and locomotion in Alzheimer's disease. NeuroImage (2024).
4. In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases. Alzheimer's Research & Therapy (2021).